Intracellular and extracellular targets for antitumour activity and toxicity of ruthenium complexes

• Unité de recherche: COST
• Numéro de projet: C02.0104
• Titre du projet anglais: Intracellular and extracellular targets for antitumour activity and toxicity of ruthenium complexes

Mots-clé (Anglais)

Bioinorganic; biorganometallic; anticancer; mechanism; ruthenium

Programme de recherche (Anglais)

COST-Action D20 - Metal Compounds in the Treatment of Cancer and Viral Diseases

Description succincte (Anglais)

First, we want to examine a number of complexes of ruthenium and of other group VIII transition metals in order to set up a sequence of experimental assays in vitro which allow to predict selective antimetastatic activity in vivo. Second, we intend to identify the nature and the biological relevance for the interaction of ruthenium complexes with the components of the extracellular matrix. Third, we want to ascertain the existence of a cell membrane receptor for ruthenium complexes, responsible for the non cytotoxic effects on solid tumour metastases. The ultimate goal of this study is that of identifying a chemical structure and a biological target for the selective treatment of solid tumour metastases by interfering with the mechanism that sustain the malignant growth. The group of laboratories of the present proposal represent a wide and integrated competence of inorganic compounds which may allow the identification of a new strategy for the study of novel metal-based drugs in cancer chemotherapy.

Autres indications (Anglais)

Full name of research-institution/enterprise: EPF Lausanne Laboratoire de Chimie Organométallique et Médicinale EPFL ISIC-LCOM-BCH2402

Partenaires et organisations internationales (Anglais)

AT, BE, BG, CZ, DK, FI, FR, DE, EL, HU, IE, IL, IT, NL, NO, PL, RO, SI, ES, SE, CH, TR, UK

Résumé des résultats (Abstract) (Anglais)

This project was concerned with the development of selective anticancer and antimetastasis drugs based on ruthenium. Two ruthenium drugs are now in clinical trials and despite having similar structures one is highly selective towards primary tumours whereas the other is highly selective towards secondary (metastasis) tumours. There are clearly considerable challenges in this area and understanding the mechanism of action of such drugs would greatly facilitate further drug development studies. In our own laboratory we have discovered a class of antitumour reagent and in this project our aim was to increase our understanding of these compounds with respect to efficacy and mode of action.

Références bases de données (Anglais)

Swiss Database: COST-DB of the State Secretariat for Education and Research Hallwylstrasse 4 CH-3003 Berne, Switzerland Tel. [phone] Swiss Project-Number: C02.0104